309 related articles for article (PubMed ID: 26141219)
1. Icotinib might be effective for the treatment of leptomeningeal carcinomatosis in non-small cell lung cancer with sensitive EGFR mutations.
Gong L; Xiong M; Huang Z; Miao L; Fan Y
Lung Cancer; 2015 Sep; 89(3):268-73. PubMed ID: 26141219
[TBL] [Abstract][Full Text] [Related]
2. A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC).
Hu X; Han B; Gu A; Zhang Y; Jiao SC; Wang CL; He J; Jia X; Zhang L; Peng J; Wu M; Ying K; Wang J; Ma K; Zhang S; You C; Tan F; Wang Y; Ding L; Sun Y
Lung Cancer; 2014 Nov; 86(2):207-12. PubMed ID: 25261231
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors.
Zhao Q; Shentu J; Xu N; Zhou J; Yang G; Yao Y; Tan F; Liu D; Wang Y; Zhou J
Lung Cancer; 2011 Aug; 73(2):195-202. PubMed ID: 21144613
[TBL] [Abstract][Full Text] [Related]
4. Effects of icotinib on advanced non-small cell lung cancer with different EGFR phenotypes.
Pan H; Liu R; Li S; Fang H; Wang Z; Huang S; Zhou J
Cell Biochem Biophys; 2014 Sep; 70(1):553-8. PubMed ID: 24777808
[TBL] [Abstract][Full Text] [Related]
5. Icotinib versus whole-brain irradiation in patients with EGFR-mutant non-small-cell lung cancer and multiple brain metastases (BRAIN): a multicentre, phase 3, open-label, parallel, randomised controlled trial.
Yang JJ; Zhou C; Huang Y; Feng J; Lu S; Song Y; Huang C; Wu G; Zhang L; Cheng Y; Hu C; Chen G; Zhang L; Liu X; Yan HH; Tan FL; Zhong W; Wu YL
Lancet Respir Med; 2017 Sep; 5(9):707-716. PubMed ID: 28734822
[TBL] [Abstract][Full Text] [Related]
6. Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer.
Ren GJ; Zhao YY; Zhu YJ; Xiao Y; Xu JS; Shan B; Zhang L
Chin Med J (Engl); 2011 Jan; 124(1):19-25. PubMed ID: 21362302
[TBL] [Abstract][Full Text] [Related]
7. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.
Shi Y; Zhang L; Liu X; Zhou C; Zhang L; Zhang S; Wang D; Li Q; Qin S; Hu C; Zhang Y; Chen J; Cheng Y; Feng J; Zhang H; Song Y; Wu YL; Xu N; Zhou J; Luo R; Bai C; Jin Y; Liu W; Wei Z; Tan F; Wang Y; Ding L; Dai H; Jiao S; Wang J; Liang L; Zhang W; Sun Y
Lancet Oncol; 2013 Sep; 14(10):953-61. PubMed ID: 23948351
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China.
Wang Y; Yuan X; Yang M; Shen Z; Chen H; He X; Ma Y; Ding L
Pharmacology; 2021; 106(11-12):658-666. PubMed ID: 34673645
[TBL] [Abstract][Full Text] [Related]
9. Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors.
Lee SJ; Lee JI; Nam DH; Ahn YC; Han JH; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2013 Feb; 8(2):185-91. PubMed ID: 23328548
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era.
Park JH; Kim YJ; Lee JO; Lee KW; Kim JH; Bang SM; Chung JH; Kim JS; Lee JS
Lung Cancer; 2012 Jun; 76(3):387-92. PubMed ID: 22186628
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer.
Lee E; Keam B; Kim DW; Kim TM; Lee SH; Chung DH; Heo DS
J Thorac Oncol; 2013 Aug; 8(8):1069-74. PubMed ID: 23804027
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of icotinib and whole-brain radiotherapy in Chinese patients with brain metastases from non-small cell lung cancer.
Fan Y; Huang Z; Fang L; Miao L; Gong L; Yu H; Yang H; Lei T; Mao W
Cancer Chemother Pharmacol; 2015 Sep; 76(3):517-23. PubMed ID: 26148750
[TBL] [Abstract][Full Text] [Related]
13. Effects of icotinib with and without radiation therapy on patients with EGFR mutant non-small cell lung cancer and brain metastases.
Fan Y; Xu Y; Gong L; Fang L; Lu H; Qin J; Han N; Xie F; Qiu G; Huang Z
Sci Rep; 2017 Mar; 7():45193. PubMed ID: 28332624
[TBL] [Abstract][Full Text] [Related]
14. [Clinical Analysis of Icotinib on Beneficiary of
Advanced Non-small Cell Lung Cancer with EGFR Common Mutation].
Jiang X; Wang W; Zhang Y
Zhongguo Fei Ai Za Zhi; 2016 Apr; 19(4):200-6. PubMed ID: 27118647
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
Lu S; Ye M; Ding L; Tan F; Fu J; Wu B
Oncotarget; 2017 Feb; 8(6):9996-10006. PubMed ID: 28036283
[TBL] [Abstract][Full Text] [Related]
16. Retrospective study of adjuvant icotinib in postoperative lung cancer patients harboring epidermal growth factor receptor mutations.
Yao S; Zhi X; Wang R; Qian K; Hu M; Zhang Y
Thorac Cancer; 2016 Sep; 7(5):543-548. PubMed ID: 27766784
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacokinetics, safety, and preliminary efficacy evaluation of icotinib in patients with advanced non-small cell lung cancer.
Liu D; Zhang L; Wu Y; Jiang J; Tan F; Wang Y; Liu Y; Hu P
Lung Cancer; 2015 Sep; 89(3):262-7. PubMed ID: 26162563
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy of icotinib in lung cancer patients with different EGFR mutation status: a meta-analysis.
Qu J; Wang YN; Xu P; Xiang DX; Yang R; Wei W; Qu Q
Oncotarget; 2017 May; 8(20):33961-33971. PubMed ID: 28430623
[TBL] [Abstract][Full Text] [Related]
19. Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy.
Masuda T; Hattori N; Hamada A; Iwamoto H; Ohshimo S; Kanehara M; Ishikawa N; Fujitaka K; Haruta Y; Murai H; Kohno N
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1465-9. PubMed ID: 21274533
[TBL] [Abstract][Full Text] [Related]
20. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis.
Liao BC; Lee JH; Lin CC; Chen YF; Chang CH; Ho CC; Shih JY; Yu CJ; Yang JC
J Thorac Oncol; 2015 Dec; 10(12):1754-61. PubMed ID: 26334749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
